<SEC-DOCUMENT>0001144204-17-043151.txt : 20170814
<SEC-HEADER>0001144204-17-043151.hdr.sgml : 20170814
<ACCEPTANCE-DATETIME>20170814161224
ACCESSION NUMBER:		0001144204-17-043151
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170814
FILED AS OF DATE:		20170814
DATE AS OF CHANGE:		20170814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bioblast Pharma Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		171030217

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v473262_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of: August 2017 (Report No.
2)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>BIOBLAST PHARMA LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">37 Dereh Menechem Begin St., 15<SUP>th</SUP>&nbsp;Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Tel Aviv 6522042 Israel</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F <FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attached hereto as Exhibit 99.1 and incorporated
by reference herein is the Registrant&rsquo;s Notice of Meeting, Proxy Statement and Proxy Card for the Extraordinary General Meeting
of Shareholders to be held on Monday, September 18, 2017 (the &ldquo;<U>Meeting</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Only shareholders of record who hold Ordinary
Shares, nominal value NIS 0.01, of the Registrant at the close of trading on the Nasdaq Capital Market on August 21, 2017, will
be entitled to notice of and to vote at the Meeting and any postponements or adjournments thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Notice of Meeting and Proxy Statement
attached to this Form 6-K of the Registrant are incorporated by reference into the registration statement on Form F-3 (File No.
333-206032) and the registration statements on Form S-8 (File No. 333-203114 and 333-210459) of the Registrant, filed with the
Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded
by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 86%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Meeting, Proxy Statement and Proxy Card for the Extraordinary General Meeting of Shareholders to be held on Monday, September 18, 2017.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioBlast Pharma Ltd.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Fredric Price</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Fredric Price</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Chairman</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 14, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v473262_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="bbp_logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>BIOBLAST PHARMA LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTICE OF EXTRAORDINARY GENERAL MEETING
OF THE SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notice is hereby given that an extraordinary
general meeting of the shareholders of Bioblast Pharma Ltd. (&ldquo;<B>Company</B>&rdquo;) will be held on September 18, 2017,
at 10:00 am Israel time, at the offices of the Company&rsquo;s counsel (Zysman, Aharoni, Gayer &amp; Co.) at &ldquo;<FONT STYLE="background-color: white">Beit
Zion</FONT>&rdquo;<FONT STYLE="background-color: white">, 41-45 Rothschild Blvd., 8<SUP>th</SUP> Fl., Tel Aviv 65784</FONT>, Israel
(the &ldquo;<B>Meeting</B>&rdquo;), for the following purpose:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">To approve a reverse split of the Company&rsquo;s share capital at the ratio of five to one and
to amend the Company&rsquo;s Amended and Restated Articles of Association accordingly.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Record Date and Right to Vote</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of Israeli law
and the Company&rsquo;s Amended and Restated Articles of Association (&ldquo;<B>Articles</B>&rdquo;), only shareholders of record as
of the close of trading on the Nasdaq Capital Market on August 21, 2017 (&ldquo;<B>Record Date</B>&rdquo;) are entitled to attend
and vote at the Meeting and any adjournments or postponements thereof. They are also entitled to notice of the Meeting and to vote
at the Meeting if they held ordinary shares of the Company par value NIS 0.01 per share (&ldquo;<B>Ordinary Shares</B>&rdquo;)
through a bank, broker or other nominee which was one of the Company&rsquo;s shareholders of record at the close of business on
the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">A
shareholder whose Ordinary Shares are registered in his, her, or its favor with a member of a stock exchange and are included in
the Ordinary Shares which are registered in the register of shareholders of the Company under the name of such member of a stock
exchange, shall be required to prove ownership of such Ordinary Shares as of the Record Date by providing the Company, before the
time appointed for holding the Meeting, with proof of ownership, issued by a member of a stock exchange, or a copy of the shareholder</FONT>&rsquo;<FONT STYLE="background-color: white">s
Identification Card, passport, or Incorporation Certificate, if such shareholder is registered in the register of shareholders
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Legal Quorum</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Articles, no business may be
transacted at any shareholders meeting unless a quorum is present when the meeting begins.&nbsp;The quorum required for a meeting
is the presence, in person or by proxy or by a voting deed, of at least two shareholders, holding in the aggregate at least one
third of the issued and outstanding Ordinary Shares as of the Record Date (&ldquo;<B>Quorum</B>&rdquo;).&nbsp;If within an hour from
the time appointed for holding a meeting a Quorum is not present, the meeting shall be dissolved and it shall stand adjourned
to the same day in the next week (or the business day following such day, if such day is not a business day) at the same time
and place and two shareholders then present at such adjourned meeting, in person or by proxy or by a voting deed, shall constitute
a Quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Abstentions are counted in determining
if a Quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Proxy</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You can vote your shares by attending the
Meeting or by completing and signing a proxy card. Attached is the proxy card for the Meeting that is being solicited by our board
of directors. If you are voting by proxy, please follow the instructions on the proxy card. We encourage all shareholders to vote
by proxy, even if attending the Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are mailing copies of this invitation
and the proxy card to our shareholders of record as of the Record Date, and we will solicit proxies primarily by mail and e-mail.
The original solicitation of proxies by mail and e-mail may be further supplemented by solicitation by telephone, mail, e-mail
and other means by certain of our officers, directors and employees (who will not receive additional compensation for these services).
We will bear the cost of external solicitors and of the solicitation of the proxy cards, including postage, printing and handling,
and will reimburse the reasonable expenses of brokerage firms and others for forwarding material to beneficial owners of our Ordinary
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will not be able to count a proxy card
unless we receive it, accompanied by a copy of (a) the shareholder&rsquo;s Identification Card, passport, or Incorporation Certificate
(if applicable), with respect to a shareholder who is registered in the register of shareholders of the Company, and (b) with proof
of ownership, as specified above, with respect to a shareholder whose shares are registered under the name of a member of a stock
exchange. We will not be able to count a proxy card unless we receive it at the offices of the Company&rsquo;s counsel (Zysman,
Aharoni, Gayer &amp; Co.) at &ldquo;Beit Zion&rdquo;, 41-45 Rothschild Blvd., 8th Fl., Tel Aviv, Israel, or at our transfer agent,
Vstock Transfer, LLC, at 18 Lafayette Place, Woodmere, NY 11598 in the enclosed envelope, by September 18, 2017 at 6:00 am Israel
time, which is September 17, 2017 at 11:00 pm Eastern time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you sign and return the enclosed proxy
card, your shares will be voted as abstained of all of the proposed resolutions, whether or not you specifically indicate a &ldquo;ABSTAIN&rdquo;
vote, unless you specifically vote &ldquo;FOR&rdquo; or &ldquo;AGAINST&rdquo; a specific resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On all matters considered at the Meeting,
abstentions will be treated as neither a vote &ldquo;FOR&rdquo; nor &ldquo;AGAINST&rdquo; the matter, although they will be counted
in determining if a Quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 5in">By
order of the Board of Directors,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 5in"><U>/s/
Mr. Fredric Price</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 5in"><U>Mr.
Fredric Price</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 5in">Executive Chairman
of the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">August 14, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="bbp_logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>BIOBLAST PHARMA LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TEL-AVIV, ISRAEL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROXY STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXTRAORDINARY GENERAL MEETING OF THE
SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Proxy Statement is furnished to the
holders of ordinary shares, New Israeli Shekel (&ldquo;<B>NIS</B>&rdquo;) 0.01 par value per share (the &ldquo;<B>Ordinary Shares</B>&rdquo;),
of Bioblast Pharma Ltd. (the &ldquo;<B>Company</B>&rdquo;) in connection with the solicitation by the Company&rsquo;s board of
directors (the &ldquo;<B>Board of Directors</B>&rdquo;) of proxies for use at the extraordinary general meeting of the shareholders,
or at any adjournment thereof, pursuant to the accompanying Notice of an Extraordinary General Meeting of Shareholders. The meeting
will be held on September 18, 2017, at 10:00 am Israel time, at the offices of the Company&rsquo;s counsel (Zysman, Aharoni, Gayer
&amp; Co.) at &ldquo;Beit Zion&rdquo;, 41-45 Rothschild Blvd., 8th Fl., Tel Aviv 65784, Israel (the &ldquo;<B>Meeting</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SOLICITATION OF PROXIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.15pt 0pt 0; text-align: justify">The agenda for the Meeting
is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.15pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">ITEM 1 &ndash; To approve
a reverse split of the Company&rsquo;s share capital at the ratio of five to one and to amend the Company&rsquo;s Amended and Restated
Articles of Association accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Background</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 12, 2017,
the Company received a staff deficiency letter from NASDAQ notifying the Company that for the past 30 consecutive business days,
the closing bid price per share of the Company&rsquo;s Ordinary Shares had been below the $1.00 minimum bid price requirement for
continued listing on the NASDAQ Capital Market, as required by NASDAQ Listing Rule 5550(a)(2) (the &ldquo;<B>Bid Price Rule</B>&rdquo;).
NASDAQ provided the Company with 180 calendar days, or until October 9, 2017, to regain compliance with the Bid Price Rule. To
regain compliance with the Bid Price Rule, the closing bid price of the Ordinary Shares must meet or exceed $1.00 per share for
a minimum of 10 consecutive business days during the 180 day grace period. In general, applicable NASDAQ rules provide that upon
meeting certain NASDAQ listing requirements, a company may be eligible for an additional grace period of 180 calendar days. However,
the Company does not meet all such NASDAQ listing requirements and therefore is not eligible for such additional grace period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company fails to
regain compliance with the Bid Price Rule and its Ordinary Shares are delisted, trading in the Ordinary Shares would be expected
to be conducted on the Pink Sheets. The Pink Sheets is generally considered to be a less efficient market than the NASDAQ Capital
Market, and the stock price, as well as the liquidity of the Ordinary Shares, could be adversely affected as a result. In order
to regain compliance with the Bid Price Rule, our Board of Directors recommends that the Company&rsquo;s shareholders effect a
reverse split of the Company&rsquo;s share capital at the ratio of five to one, as detailed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is proposed that the
following resolution be adopted at the Meeting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>RESOLVED</B>,
to approve a reverse split of the Company&rsquo;s share capital at the ratio of five to one, so each five ordinary shares, par value
NIS 0.01 per share, shall be consolidated into one ordinary share, par value NIS 0.05 (the &ldquo;<B>Reverse Split</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>RESOLVED</B>, that
the Board of directors of the Company is authorized to cause any shareholders (and any other security holders) who otherwise would
be entitled to receive fractional shares as a result of the Reverse Split, because they hold a number of shares not evenly divisible
by five, to be automatically entitled to receive an additional fraction of a share to round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>RESOLVED</B>, to approve
and to amend the Company&rsquo;s Amended and Restated Articles of Association to reflect the Reverse Split, such that as a result,
the authorized share capital of the Company shall be NIS 500,000 divided into 10,000,000 ordinary shares, par value NIS 0.05 per
share, and Article 2.1.1 of the Company&rsquo;s Amended and Restated Articles of Association will be replaced in its entirety with
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registered capital
of the Company is NIS 500,000 divided into 10,000,000 ordinary shares with a par value of NIS 0.05 each.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>BIOBLAST PHARMA
LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROXY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">THIS PROXY IS SOLICITED
ON BEHALF OF THE BOARD OF DIRECTORS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby
appoints Mr. Fredric Price, Executive Chairman of the Board of Directors and Chief Executive Officer, Mr. Chaime Orlev, and Mr.
Oren Elmaliah, and each of them, as agents and proxies of the undersigned, with full power of substitution to each of them, to
represent and to vote on behalf of the undersigned all the ordinary shares, New Israeli Shekel (&ldquo;<B>NIS</B>&rdquo;) 0.01
par value per share (the &ldquo;<B>Ordinary Shares</B>&rdquo;), of Bioblast Pharma Ltd.&nbsp;(the &ldquo;<B>Company</B>&rdquo;)
which the undersigned is entitled to vote at the extraordinary general meeting of shareholders (the &ldquo;<B>Extraordinary General
Meeting</B>&rdquo;) to be held at the offices of the Company&rsquo;s counsel (Zysman, Aharoni, Gayer &amp; Co.) at &ldquo;Beit
Zion&rdquo;, 41-45 Rothschild Blvd., 8th Fl., Tel Aviv, Israel, on September 18, 2017, at 10:00 a.m. Israel time, and at any adjournments
or postponements thereof, upon the following matter, which is more fully described in the Notice of Extraordinary General Meeting
of Shareholders and Proxy Statement relating to the Extraordinary General Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Proxy, when properly
executed, will be voted in the manner directed herein by the undersigned. If no direction is made with respect to any matter, this
Proxy will be voted as abstained for such matter, whether or not you specifically indicate a &ldquo;ABSTAIN&rdquo; vote.&nbsp;Any
and all proxies heretofore given by the undersigned are hereby revoked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Continued and
to be signed on the reverse side)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>BIOBLAST PHARMA
LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>September 18, 2017
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">PLEASE SIGN, DATE
AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">To approve a reverse split of the Company&rsquo;s share capital at the ratio of five to one and
to amend the Company&rsquo;s Amended and Restated Articles of Association accordingly (as more fully described in the attached
Proxy Statement).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR</B></FONT></TD>
    <TD STYLE="width: 30%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AGAINST</B></FONT></TD>
    <TD STYLE="width: 35%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABSTAIN</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In their discretion, the proxies are authorized
to vote upon such other matters as may properly come before the Extraordinary General Meeting or any adjournment or postponement
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________</FONT></TD>
    <TD STYLE="width: 35%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________</FONT></TD>
    <TD STYLE="width: 35%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">____________, 2017</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAME</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATE</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________</FONT></TD>
    <TD STYLE="width: 35%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________</FONT></TD>
    <TD STYLE="width: 35%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">____________, 2017</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NAME</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DATE</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please sign exactly as your name appears
on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, trustee or guardian,
please give full title as such. If the signed is a corporation, please sign full corporate name by duly authorized officer, giving
full title as such. If signer is a partnership, please sign in partnership name by authorized person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>bbp_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bbp_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !8 0H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@#"U
M;Q39:;NCC/VBX'&Q#PI]S7$:AKNH:E,))9V0*<HD9VJI]O?WJA-_KY/]X_SI
ME?"XS,Z^);3=H]E_6I]7AL#2HJZ5WW9U>D^,YH-L.HJ9H^GFK]\?7UKM+2]M
MK^ 36LRRH>ZGI]1VKR"NU\!?ZJ^_WD_]FKTLHS*O.JJ%1W3Z]=OQ.+,<%2C3
M=6"L_P #L:***^H/!.3^)G_).M8_ZYI_Z&M6_ G_ "(FB?\ 7G'_ "JI\3/^
M2=:Q_P!<T_\ 0UKC?"FC>+/%/A;3Y$\02:+I<40AMX[5"9) OREV8$$9(..?
MP[GOITU/"ZRLN;]#FE)QK:*^GZGKU%><?\*RU@<KX]UH-Z[W_P#BZR;[4/%?
MPUU:PDU366UG1+F3RY'F4[T]>I)!QR.2#@UG'"QF[4YIOM9K\RG6<=9QLOD=
MOXX\)GQEHD6G"]%IY=PL_F>5YF<*PQC(_O?I721IY<2)G.U0,UP7Q>U2^TKP
MA;7&G7DUK*UZB&2!RI*E'.,CMP/RK6\:>*&\*>#SJ2*LET^R* /T+L,Y/T )
M_"DJ=2=.$4[IMV7GI<?/",I-]$KG4T5Y;IO@WQEKUC#J&K>-+ZRDG02"WMLK
MM!Y .UE /MBK9^&>MJ,P^/\ 64;L2SD?^C!3>'I)V=57]&"JS>J@_O1Z/7F'
MCO\ Y*EX,_ZZ?^SBFZ)KOB/PMXYMO"_B.^&H6UZN;:Z(^8$YQSUY(((.>HYQ
MUI_%2ZN;+QSX8N+*$3729\F-NC/O 4'\<5OAZ$H5TKWO%V?39F56HI4[]FOS
M/7:*\Y/@+Q5J(\_4_'5]%,_+16:LD:GT&&&?R%-;X;>((ANM/'^K+(.@D+E3
M]?GKG]A2ZU5]S-?:3_D_%'I%>9+_ ,G -_V#_P#V6K'@;Q/K2^)=0\)>)9$F
MOK5=\5PH WJ,<' &<A@0<9ZYJNO_ "< W_8/_P#9:VI4I4I5(O\ E?Z$3FIJ
M+7<]-HKSKQQJ7B6]\6:;X8T&:2QBN(_,GO50\?>XW=L!<\8))%-'PSUEAF7Q
M]K+/W(9Q_P"SUBL/%14IS2OY-_D6ZKNU&-['H]%>5:OX/\7^'=,N-4TSQK?W
M;6J&9H+G<0RJ,G&YF!.!TQ75^&?%C:OX 'B"YB42PPRM.B< M'G./3.,_C2G
MA[1YX24E>W7?YCC5N^62LSJJ*\>\.:?XP^(-E)K-SXLN-,M7E9(X;0$<#KPK
M+@=N23Q6U_PK+5QT\>:T#Z[W_P#BZN6&IP?+.HDUY-DJM*2O&.GJCT>JNIWJ
MZ9I-Y?NA=;6!YBH."P52<?I7F-U;^,? NM:9(-:O->TVYF$<\<L;.R+D9ZEB
M.#P<]N:U/'WA?6;FVUG5X?%5W;62VCN=.1"48+'RN=X&&P<\=^]"PT>>-YJS
MZZ][6[H'5?*[1U1U?A;Q#'XH\/P:M%;M;I*S 1LVXC:Q'7\*V:\6\#>#-=U;
MPA9WUCXRO=-MY3)MM8HV*IAV!Y#CJ1GIWKHO^%=^*/\ HHNI?]^F_P#CM56P
M]&-2251+7:S%"K4<4^6_W'H]%(!@ $YI:X3H"BJNH:C9:59O=W]S%;6Z?>DD
M; ^GN?:O*->^-ZQ7JQ:%8)/;HWSS7.5\P?[*CD?4_E6]##5:[_=HSJ5H4_B8
MV;_7R?[Q_G7H'AK1]/.BPSO;Q323*2[.H;OTYZ5@:)J_AWXBV[M;J;'547=+
M$<;OKZ.OOP?7%*]KXB\/L;>V:1H9&^4Q+O4GZ$'!KY%8"KE6(<L13YH^2O;Y
M?UZGT+Q4,?14:4^5^?\ F4?$ME;V&M2PVV!&0&V#^$GM_GUK>\!?ZJ^_WD_]
MFJ*Q\)2S,U[K<Y4'YW3=R?=F[4Z?Q9;V!6VTBSC$"'EF! ;Z#^IKIRO*J]3%
M/$\O+'6R]?R_K0PQ^/I0H>PYN9Z:^GYG:45CZ5XCLM4P@;R;@_\ +)SU^A[U
ML5]!*$HNTD>1&2DKHY/XF?\ ).M8_P"N:?\ H:U9\ [1X"T39C'V5.GKW_6F
M?$*TN+[P'JMM:02SSR1J$BB0LS?.IX Y-<7X<U7QAX,\/V=G<^&+G4[(QAXF
M@W++#NY*.F">"3V'^'93I^TPW+%J_-M=+H<\I<M:[6EOU/6J\V^-VW_A";;=
MU^WIM_[X>G?\+0U \+X(UHMZ>6W_ ,361J%EXI^)FJV$.H:))HVB6TGF2"<D
M._KU ).,@<8&3DU>&H3HU54J626NZ_S%5J1G!PAJWY,M_%[=_P *VTK=][[5
M#GZ^4],^-.?^$.TC^Y]J7/\ W[;_ .O6K\7],O=3\'VUOIUE/=2K>HQCMXBY
M"A'&<#MR/SK7\:^%W\5>#CIT;*EU'LF@+\#>HQ@^F02/QJJ-6,%2E)[2E^A-
M2#DYI=D=2FW8NS&W'&/2EKRW3?&WBW0;&'3]9\&:A=26Z"/[3;!B' & 3A2"
M?<&K9^*&IL,0^!M:D?L"C#G\$-<[P56^EFO5?YFJQ$+:_D_\BG\1\?\ "Q?!
M!3'F?:US]/-3_P"O3_'NW_A:/@S?C'FCKZ[QC]:;HNB^(O%GCJV\3^(=/_LV
MSL5Q;6K'YB1G''7@G)) Z 8]#XF:'K.K>+_#TFD6\^^($BY6)FCA<,"I8@8
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M-I&DWL]UJMAJ]D('$T'EA)-A4Y*D*.0.>O;H:L_"F*"X^&+PW1 MY))TD).
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MG%=QXR<'P+K;J<AK"7!]BAKSKQ'<>)_B4EGI,/ABZTNR2X$LEQ=Y'0$9Y X
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MD#"C&>GYUJPPQ6\2Q0QK'&O15& *?65;$RJ:+1%TJ"AKU.+^+'_)-M4^L/\
MZ-2HK;X8Z ]K$YDU++("<7K^GUKJM9T>RU[2YM-U",R6LVW>H8J3@AAR.>H%
M7418XU1>%4 #Z41Q$H4E"#L[M_D4Z2E-RDNAQC?"OPW(-LOV^1.ZO>.0?UKJ
MM,TNRT;3XK'3[=+>VB&%C7^>3R3[FK=%9SK5)JTI-E1IQB[I' >);.UO_BKX
M9M[RVAN(&M;C=',@=3A21D'BNG_X1/PY_P!"_I7_ (!Q_P"%6+C1;&YUJTU>
M6-C>6B.D+[R  PP>.AK0JIUFXQ46U96_%BC35VVMV<KXA\,>'X?#.JRQ:%IB
M2)9S,KK:1@J0AP0<<&I/A[_R(&B_]>X_F:Z"[MHKVSGM)U+0SQM&X!QE6&#S
M]#46F:=;:1IL&GV:%+:!=D:EB2!]30ZMZ7(VV[W_  !0M/F78X7XD7M_J\]O
MX/T6$W%U<K]HO%60)MA4\*6/ R?Z>M:%OJ?C.TMHK:W\%VD<,2!(T74TPJ@8
M Z5T=EH.GV&K7VJ01-]MO2/.E=RQ('0#/0>P]!Z5I5;KQ4%!132[WWZ[,E4V
MY.3=G^AY+K%WXDT;Q/:^,;WP^EA:Q*+;4##=K-YL3$ $@ '(XY]A7J\4L<\*
M31.KQR*&1E.0P/((J.\M(+^RFL[J,203H8Y$/1E(P14>EZ;;:/IL&GV@<6\"
M[8P[EB!Z9/-35JQJ16EFM/E_P!P@X-ZW3_,\XL/#&E^)/B/XP&I12OY#V_E^
M7,\>-R'/W2,]!70_\*P\+?\ /K=?^!DO_P 570V6B6-AJE_J5O$RW5^4-PQ<
MD-M!"\=!P>U:%54Q51M<DFE9?@A1HQM[R5]3R[6/#EAX(\3>'=2T>,C[9?I9
MSI.?-^5^,JS992.>AKU&L_5-$L=8>R:]B9S9W"W,.'*[9%Z'CK]*T*BK5]I&
M-]6KW^_0J$.1NVQPOPX_X^O%O_8<N/YU3N?^+>^-?M@^3P[K<FV<?PVMQV;V
M!_Q_NBNVTO1+'1WO6LHF0WEPUS-ERVZ1NIYZ?2GZMI-EK>F3:?J$(FMI@ RD
MXZ'(((Z'-:.O%U6W\+T?W+\4U=$>S?(EU1Q.CJ?'?C!M?F!.AZ4YBTY#TFE_
MBE^@[?AZ&K/C?_D<?!/_ %_2?R6NQT[3[72M/@L+*(16T"!(T'8?U/O4&H:)
M8ZG?6%Y=1,\]A(9+=@Y&UCC/ Z].]"KQ]I?[*32^Y_\ #L?LWR6ZO5FA7D\U
M[K7BCQT=<TG2$U/2](=[:U$ERL2&7C=(,YS[?137J=S;I=6LMO(6"2H48HQ4
MX(P<$<CZU7TG2;+0],AT[3X1#;0@[5R3U.223U.36=&K&DF[7;T^77_(JI!S
M:5]#FSK?C@C!\'6N/^PFG^%87@BYU#PQXFG\/ZO8#3[74V>ZT^(3"1(V_BC#
M#VYQ[>]>G5FZOH6GZW]E-[$S/:3">!T<HR..X(_E[5<:\+.#BDGVO\MV2Z<K
MJ2>J-*BBBN4V"BBB@ HHHH **** "BBB@ HK$\6?\B[<?[R?^A"LS7=8%UH,
ML L+^(G9^\EAVJ,$=\UM"BYI-=69SJ*+:9UU%8AU:[:XGMK*S246J(9&>7;D
MD9P!BF)XAEN6LDM;,.]U$S@-)C:02#DXZ<&E[&8>TB;U%8#^)&AM)3-:JES'
M<"W*>9\N3R#NQP.#5G3-8:]O9;25(1(B"0/!+YBD9QU]:3I32NT-5(MV-:BL
M?4-9>TU);*-+<,8O,,EQ-Y:]<8''6L^]O;B>]T.X%J//+3 1"4$$X ^\.,=Z
M<:,G:XG42.HHK!;Q#)#;W?GV8%S;R)'Y:R9#%NG.*>VM75M-+!>6:1R+;O.A
M27<&VCH>.*/8S#VD3;HK*;6&6WTN7R1_IK*I&[[F1G\:R=-U*2RL_)@@$T]Q
M>RHBLVT#&,DFA49-7!U$F=716!H[S2>(=6:>(12[8MR!MP'R]C5FYU2Z35FT
M^UM$E<0B7<TFT#G'/%)TGS67:XU-6NS6HK!7Q#)-;6GDV8-U<2/'Y;28"E>I
MSBJ]_KE\NGZA&(%M[NU*;V5]P"MW''TX]ZI4)MV$ZL;7.FHJII\MY+!NNX8X
MS@;=C[MW'4\#%84%U>6VK:TUK:K,%=7<M)MP IX'J:F--NZ[#<TK/N=116 _
MB7?]D6"*%7GA\XF>8(JC.,9QR<@UH:3J0U2T:;8$9)#&P5MPR/0]QS1*E**N
MT"J1;LB_16$VN7AFNA#IWFQ6T_E.5<EB,]0,4EYKUQ:R7)^S6_EP-C:UP!(X
M]0N*?L9["]I$WJ*PY];NC=2PV=B)O+@6?)?!((SC&.33)O$4@N##%!"C)$DC
MBYF\L@L,[0,=:%1FP]I$WZ*S;74I;VQ@O((<I(N2G4@A@",_G^5-:]U'>VRQ
M7;GC<QSCWXJ?9N]BN=;FI1114%!1110 4444 %%%% %#6-/;5-,DM%D$9<@[
MB,XP<TFJZ<VHZ2]DL@1FV_,1GH0?Z4452G)6MT)<4[WZE632+V*[N9[*[BC%
MRBK(LD>[! QD<UFMI\MCK&E6=K.%DBMWQ(Z9!.23D9]S116U.I)W3[/\C.<$
MMNY=;P[+);2F6Z4W;W(N-_E_*".@QGIR:O6%A=07,D]S/$VY=JQPQ;%'OZYH
MHK-U9-69:IQ3NAFH:=<75VLT<ELZ!-IAN8=Z@YZCOFJUGX>:TDL&%PK?9GD=
MAMP"7 &!Z 8HHH5625D#IQ;N+<Z UR^H-]H"&YDCDC(7.PKZ^M.&C7-S<R3Z
MA=1NQMV@411[0 W4\GK111[6?]?UY![.)%%H=[FP6:]C>*R=2BK'C('J<]:!
MX?GCBB:&Z1;B*Y>=&*97#=B***?MIB]E$N:=IL]K?W=W<7"2R7 3.U-H&T8J
M5;!EUQ]0\P;6@$6S'/7.:**ESDW<I025C.7P_/%% T-TBW$$[RHQ3*D-U!&:
M?_8,L]OJ/VJZ5KB]"@LB85=O3C-%%5[:9/LHEW3;.[M3*]W=^>S[0JJ"%0 8
MX&>_>J4FCWRW5]-:WD2"[(W*\><#&..>M%%)5))MCY%:PW_A'Y(&M)+2>+S(
M(?)831;E<9SG&>.2:T].M);.V*33"61G+DA H&>P'I112E4E)68*"3NAFGV#
M64][(T@;[1,90 /N^U9<WAN9TO(4FMC'<2&3?)#F12>V<]***:JR3N@=.+5C
M0LM,:UU![DRA@T"1;0/[HZU!=:1<'4IKRUF@!G55=9HM^"!@$<T44O:2O<.1
>6L:-C;M:6<<#RF5U'+E0,G.>E6***EN[N6E;0__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
